Stock Analysis of Bone Biologics Corp. WT (BBLGW) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BBLGW
Close 35.02
Change -4.98 / 12.45 %
Volume 2035.00
Vol Change 568.00 / 38.72 %
IndustryMedical Devices
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Bone Biologics Corp. WT
PE (TTM)

-7.71

Very Poor
Price / Book

12.49

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

0

Enterprise Value

0

ROA (TTM)

-113.22

Very Poor
ROE (TTM)

-162.02

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

338.19 %

-6505.39 K
Debt to Equity

0

Excellent
Altman Z Score

-35.12

Very Poor
Quick Ratio

4.89

Very Good
Cash Ratio

3.64

Very Good


Highs/Lows of Bone Biologics Corp. WT
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week24.01 45.86 % 1.54 % 46.824.0116-May-2410-May-24
Two Week23.79 47.20 % 3.42 % 46.819.0116-May-2408-May-24
One Month19.0 84.32 % 5.60 % 46.819.0116-May-2408-May-24
Three Month5.0 600.40 % 5.95 % 46.82.8716-May-2423-Feb-24
Six Months2.9995 1067.53 % 17.48 % 46.80.7216-May-2415-Dec-23
One year0.03 116633 % 27.52 % 46.80.01916-May-2406-Jun-23
Two year0.19 18331.58 % 29.70 % 46.80.00216-May-2404-Nov-22


Technical View of Bone Biologics Corp. WT
RSI

67.41

Strong Bearish
MACD

4.42

Bullish
ADX

21.55

Neutral
Super Trend

30.74

Mild Bullish
Williams %R

-42.39

Strong Bearish
CCI

220.21

Mild Bearish


EMA 5

32.46

Strong Bullish
EMA 15

26.58

Strong Bullish
EMA 50

19.27

Strong Bullish
EMA 100

14.47

Strong Bullish
SMA 100

11.73

Strong Bullish
SMA 200

8.12

Strong Bullish
SMA 5 / 20

31.65 / 23.59

Strong Bullish
SMA 15 / 50

25.86 / 17.66

Strong Bullish
SMA 50 / 200

17.66 / 8.12

Strong Bullish




Charts of Bone Biologics Corp. WT


Returns of Bone Biologics Corp. WT with Peers
Period / StockBBLGWTIVCMOTSQSAMUTRS
1 Week45.86%-6.75%14.47%2.60%0%
1 Mth84.32%-57.76%-66.93%12.16%-99.82%
3 Mth600.40%-62.02%-86.90%55.14%-99.88%
6mth1067.53%-73.39%-98.04%59.62%-99.97%
1 Year116633%-96.31%-99.16%38.91%-99.98%
2 Year18331.58%-99.71%-99.89%43.10%-100.00%
5 Years---99.99%2113.33%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Bone Biologics Corp. WT with Peers
Ratio / StockBBLGWTIVCMOTSQSAMUTRS
PE-7.71-27.35-1.39-5.01-0.0232
P/B12.4952.3878.63-49.990.051
ROA-113.22-140.14-112.45-576.91-66.79
ROE-162.02-191.53-5665.200-217.71
Debt To Equity00.0540.9080.04600
Revenue0
% 		1227.00 K
66584.78 % 		364000
38.51 % 		0
% 		51693.00 K
2.78 %
Net Income-6505.39 K
338.19 % 		-8255.00 K
81665.06 % 		-13744.00 K
26.10 % 		-5085.07 K
16.29 % 		-33450.00 K
1.94 %


Technicals of Bone Biologics Corp. WT with Peers
Technical / StockBBLGWTIVCMOTSQSAMUTRS-
ADX21.5514.9940.1224.4335.70
CMF0.356-0.078-0.4050.4950.0444
MFI67.4683.255.8666.662.82
RSI67.4127.7621.8168.6930.41
MACD Abv SignalTrueFalseTrueFalseFalse
Price Above 50 MATrueFalseFalseTrueFalse-
Price Above 200 MATrueFalseFalseTrueFalse-


About : Bone Biologics Corp Warrants

Address : 2 Burlington Woods Drive, Burlington, MA, United States, 01803
Tel : 781 552 4452
URL : https://www.bonebiologics.com
Code : BBLGW, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 13_Oct_2021
Employee Count : 2

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)